Unknown PHASE2 INTERVENTIONAL 2-arm NCT01782170

Efficacy of Iocide Oral Rinse Against Gingival Inflammation

Phase II Study: Evaluate Efficacy of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects on Biological Markers Indicative of Systemic Disease

Sponsor: Biomedical Development Corporation

Conditions Gingivitis Investigation of Biological Markers of Inflammation

Interventions Iocide Oral Rinse Placebo

Updated 6 times since 2017 Last updated: Aug 13, 2013 Started: Feb 28, 2013 Primary completion: Jan 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01782170, this PHASE2 trial focuses on Gingivitis and Investigation of Biological Markers of Inflammation and remains ongoing. Sponsored by Biomedical Development Corporation, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomedical Development Corporation
National Heart, Lung, and Blood Institute (NHLBI)
University of Kentucky

Data source: Biomedical Development Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States